Kathrin Maria Bernt

Dr. Kathrin Maria Bernt


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Cancer Cell
Verified
Journal Article
Closed access
SDScott R. Daigle
Scott R. Daigle
EOEdward J. Olhava
Edward J. Olhava
CTCarly A. Therkelsen
Carly A. Therkelsen
CMChristina R. Majer
Christina R. Majer
CSChristopher J. Sneeringer
Christopher J. Sneeringer
RPRoy M. Pollock
Roy M. Pollock

1 July 2011 in Cancer Cell
Verified
Journal Article
Closed access
KBKathrin Maria Bernt
Kathrin Maria Bernt
NZNan Zhu
Nan Zhu
ASAmit U. Sinha
Amit U. Sinha
SVSridhar Vempati
Sridhar Vempati
JFJoerg Faber
Joerg Faber
SAScott A. Armstrong
Scott A. Armstrong

4 March 2012 in Nature
Verified
Journal Article
Open access
PDF file
TOTamer T. Onder
Tamer T. Onder
NKNergis Kara
Nergis Kara
ACAnne Cherry
Anne Cherry
ASAmit U. Sinha
Amit U. Sinha
NZNan Zhu
Nan Zhu
GDGeorge Q. Daley
George Q. Daley
Inhibition of DOT1L, the H3K79 histone methyltransferase, increases cell reprogramming and substituted for KLF4 and c-Myc, showing that chromatin-modifying enzymes act not only as facilitators but also as barriers to reprogramming. A study of the role of chromatin-modifying enzymes in the reprogramming of human fibroblasts to induced pluripotent stem (iPS) cells suggests that such enzymes can act as facilitators — but also as barriers — to epigenetic remodelling. By knocking down 22 selected genes involved in DNA and histone methylation pathways, George Daley and colleagues identified both positive and negative regulators of iPS-cell generation. In particular, inhibition of DOT1L, the H3K79 histone methyltransferase, increased reprogramming and substituted for KLF4 and c-Myc, two of the factors needed in the reprogramming cocktail. The effect of DOT1L inhibition seems to be associated with increase in the reprogramming factors NANOG and LIN28. This work demonstrates that specific chromatin modifiers can be modulated to generate iPS cells more efficiently and with fewer exogenously introduced transcription factors. Generation of induced pluripotent stem cells (iPSCs) by somatic cell reprogramming involves global epigenetic remodelling1. Whereas several proteins are known to regulate chromatin marks associated with the distinct epigenetic states of cells before and after reprogramming2,3, the role of specific chromatin-modifying enzymes in reprogramming remains to be determined. To address how chromatin-modifying proteins influence reprogramming, we used short hairpin RNAs (shRNAs) to target genes in DNA and histone methylation pathways, and identified positive and negative modulators of iPSC generation. Whereas inhibition of the core components of the polycomb repressive complex 1 and 2, including the histone 3 lysine 27 methyltransferase EZH2, reduced reprogramming efficiency, suppression of SUV39H1, YY1 and DOT1L enhanced reprogramming. Specifically, inhibition of the H3K79 histone methyltransferase DOT1L by shRNA or a small molecule accelerated reprogramming, significantly increased the yield of iPSC colonies, and substituted for KLF4 and c-Myc (also known as MYC). Inhibition of DOT1L early in the reprogramming process is associated with a marked increase in two alternative factors, NANOG and LIN28, which play essential functional roles in the enhancement of reprogramming. Genome-wide analysis of H3K79me2 distribution revealed that fibroblast-specific genes associated with the epithelial to mesenchymal transition lose H3K79me2 in the initial phases of reprogramming. DOT1L inhibition facilitates the loss of this mark from genes that are fated to be repressed in the pluripotent state. These findings implicate specific chromatin-modifying enzymes as barriers to or facilitators of reprogramming, and demonstrate how modulation of chromatin-modifying enzymes can be exploited to more efficiently generate iPSCs with fewer exogenous transcription factors.

9 February 2017 in Frontiers in Pediatrics
Verified
Journal Article
Open access
AWAmanda C. Winters
Amanda C. Winters
KBKathrin Maria Bernt
Kathrin Maria Bernt
The Mixed-lineage leukemia 1 (MLL1) gene (now renamed Lysine [K]-specific MethylTransferase 2A or KMT2A) on chromosome 11q23 is disrupted in a unique group of acute leukemias. More than 80 different partner genes in these fusions have been described, although the vast majority of leukemias result from MLL1 fusions with one of about six common partner genes. Approximately 10% of all leukemias harbor MLL1 translocations. Of these, two patient populations comprise the majority of cases: patients younger than one year of age at diagnosis (primarily acute lymphoblastic leukemias), and young- to-middle-aged adults (primarily acute myeloid leukemias). A much rarer subgroup of patients with MLL1 rearrangements develop leukemia that is attributable to prior treatment with certain chemotherapeutic agents – so-called “therapy related leukemias”. In general, outcomes for all of these patients remain poor when compared to patients with non-MLL1 rearranged leukemias. In this review we will discuss the normal biological roles of MLL1 and its fusion partners, how these roles are hypothesized to be dysregulated in the context of MLL1 rearrangements, and the clinical manifestations of this group of leukemias. We will go on to discuss the progress in clinical management and promising new avenues of research which may lead to more effective targeted therapies for affected patients.

2 November 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
CDCaroline Diorio
Caroline Diorio
SHSarah E. Henrickson
Sarah E. Henrickson
LVLaura A. Vella
Laura A. Vella
KMKevin O. McNerney
Kevin O. McNerney
JCJulie Chase
Julie Chase
HBHamid Bassiri
Hamid Bassiri
BACKGROUND. Initial reports from the severe acute respiratory coronavirus 2 (SARS–CoV-2) pandemic described children as being less susceptible to coronavirus disease 2019 (COVID-19) than adults. Subsequently, a severe and novel pediatric disorder termed multisystem inflammatory syndrome in children (MIS-C) emerged. We report on unique hematologic and immunologic parameters that distinguish between COVID-19 and MIS-C and provide insight into pathophysiology. METHODS. We prospectively enrolled hospitalized patients with evidence of SARS–CoV-2 infection and classified them as having MIS-C or COVID-19. Patients with COVID-19 were classified as having either minimal or severe disease. Cytokine profiles, viral cycle thresholds (Cts), blood smears, and soluble C5b-9 values were analyzed with clinical data. RESULTS. Twenty patients were enrolled (9 severe COVID-19, 5 minimal COVID-19, and 6 MIS-C). Five cytokines (IFN-γ, IL-10, IL-6, IL-8, and TNF-α) contributed to the analysis. TNF-α and IL-10 discriminated between patients with MIS-C and severe COVID-19. The presence of burr cells on blood smears, as well as Cts, differentiated between patients with severe COVID-19 and those with MIS-C. CONCLUSION. Pediatric patients with SARS–CoV-2 are at risk for critical illness with severe COVID-19 and MIS-C. Cytokine profiling and examination of peripheral blood smears may distinguish between patients with MIS-C and those with severe COVID-19. FUNDING. Financial support for this project was provided by CHOP Frontiers Program Immune Dysregulation Team; National Institute of Allergy and Infectious Diseases; National Cancer Institute; the Leukemia and Lymphoma Society; Cookies for Kids Cancer; Alex’s Lemonade Stand Foundation for Childhood Cancer; Children’s Oncology Group; Stand UP 2 Cancer; Team Connor; the Kate Amato Foundations; Burroughs Wellcome Fund CAMS; the Clinical Immunology Society; the American Academy of Allergy, Asthma, and Immunology; and the Institute for Translational Medicine and Therapeutics.

30 March 2015 in Nature Medicine
Verified
Journal Article
Open access
PDF file
CCChun-Wei Chen
Chun-Wei Chen
RKRichard P Koche
Richard P Koche
ASAmit U Sinha
Amit U Sinha
ADAniruddha J Deshpande
Aniruddha J Deshpande
NZNan Zhu
Nan Zhu
SAScott A Armstrong
Scott A Armstrong
The authors uncover the mechanism by which DOTL1 exerts its role as an epigenetic regulator required for leukemic progression by counteracting the effects of the chromatin regulators SIRT1 and SUV39H1. Rearrangements of MLL (encoding lysine-specific methyltransferase 2A and officially known as KMT2A; herein referred to as MLL to denote the gene associated with mixed-lineage leukemia) generate MLL fusion proteins that bind DNA and drive leukemogenic gene expression. This gene expression program is dependent on the disruptor of telomeric silencing 1–like histone 3 lysine 79 (H3K79) methyltransferase DOT1L, and small-molecule DOT1L inhibitors show promise as therapeutics for these leukemias. However, the mechanisms underlying this dependency are unclear. We conducted a genome-scale RNAi screen and found that the histone deacetylase SIRT1 is required for the establishment of a heterochromatin-like state around MLL fusion target genes after DOT1L inhibition. DOT1L inhibits chromatin localization of a repressive complex composed of SIRT1 and the H3K9 methyltransferase SUV39H1, thereby maintaining an open chromatin state with elevated H3K9 acetylation and minimal H3K9 methylation at MLL fusion target genes. Furthermore, the combination of SIRT1 activators and DOT1L inhibitors shows enhanced antiproliferative activity against MLL-rearranged leukemia cells. These results indicate that the dynamic interplay between chromatin regulators controlling the activation and repression of gene expression could provide novel opportunities for combination therapy.